Clinical and spectroscopic improvement in HIV-associated cognitive impairment.
To assess the impact of highly active antiretroviral therapy (HAART) on AIDS-associated cognitive impairment, 22 patients with AIDS with (n = 11) and without (n = 11) cognitive deficit were evaluated clinically and by MRS every 3 months for 9 months. Nineteen patients were on HAART at study entry, 21 after 2 months. Cognitively impaired patients presented with a subcorticofrontal deficit and decreased N-acetyl-aspartate in frontal white matter. These clinical and metabolic abnormalities reversed partially on HAART, whereas they remained within normal limits in cognitively unimpaired patients.
Stankoff
B
B
Fédération de Neurologie I, Hôpital Pitié Salpêtrière, and University Paris VI, France.
Tourbah
A
A
Suarez
S
S
Turell
E
E
Stievenart
J L
JL
Payan
C
C
Coutellier
A
A
Herson
S
S
Baril
L
L
Bricaire
F
F
Calvez
V
V
Cabanis
E A
EA
Lacomblez
L
L
Lubetzki
C
C
D015526:AIDS Dementia Complex / Q000175:diagnosis* / Q000188:drug therapy*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D009483:Neuropsychological Tests; D011446:Prospective Studies; D016896:Treatment Outcome